Key clinical point: Many patients who could undergo partial nephrectomy are still receiving radical nephrectomies.
Major finding: In 2014, 53% of patients with pT1a or pT1b RCC underwent partial nephrectomy.
Study details: Retrospective analysis of 142,000 patients.
Disclosures: The study was funded internally. Dr. Cahn reports having no relevant financial disclosures.
Cahn D et al. AUA Annual Meeting, Abstract PD07-04
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001
One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617